| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-03-20 | BL-1020 | schizophrenia |
2-3 | BiolineRx (Israel) | Mental diseases |
| 2013-03-20 | oral insulin (NN1954 - OI362GT) | type 1 and type 2 diabetes | 1 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2013-03-20 | DT-200 | Duchenne muscular dystrophy |
DART Therapeutics (USA) | Genetic diseases - Neuromuscular diseases - Rare diseases | |
| 2013-03-19 | linagliptin (Tradjenta® in the US and Trajenta® in Europe) | patients with type 2 diabetes with prevalent albuminuria | 3b | Boehringer Ingelheim (Germany) Eli Lilly (USA) | Metabolic diseases |
| 2013-03-18 | safinamide | Parkinson's disease | 3 | Newron Pharmaceuticals (Italy) | Neurodegenerative diseases - CNS diseases |
| 2013-03-18 | VBY-891 | psoriasis | 1 | Leo Pharma (Denmark) Virobay (USA) | Autoimmune diseases - Dermatological diseases |
| 2013-03-18 | BioChaperone® PDGF-BB (Platelet Derived Growth factor) | diabetic foot ulcer | 3 | Adocia (France) | Metabolic diseases - Cardiovascular diseases |
| 2013-03-14 | selumetinib | differentiated thyroid cancer | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2013-03-11 | Limtop® (imiquimod) | actinic keratinosis | 2 | Moberg Derma (Sweden) | Dermatological diseases |
| 2013-03-11 | Metalyse® (tenecteplase, TNK-tPA) | myocardial infarction | Boehringer Ingelheim (Germany) | Cardiovascular diseases | |
| 2013-03-07 | TroVax® (MVA-5T4) in combination with first-line chemotherapy agents pemetrexed and cisplatin | mesothelioma | 2 | Oxford Biomedica (UK) | Cancer - Oncology |
| 2013-03-07 | RSV vaccine candidates including AMV602 | prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus) | preclinical data | AmVac (Switzerland) | Respiratory diseases - Infectious diseases |
| 2013-03-06 | dolutegravir | Hiv-Aids | 3 | ViiV Healthcare (UK-USA) Shionogi (Japan) | Infectious diseases |
| 2013-03-05 | BACE inhibitor R7921 and anti-Abeta-antibody gantenerumab | Alzheimer\'s disease | preclinical | Roche (Switzerland) reMYND (Belgium) | Neurodegenerative diseases |
| 2013-03-04 | MT-102 | cachexia | 2 | PsiOxus Therapeutics (UK) | |
| 2013-03-04 | POL7080 (murepavadin) | infections caused by multi-drug resistant Pseudomonas | 1 | Polyphor (Switzerland) | Infectious diseases |
| 2013-03-04 | ND0612 (levodopa and carbidopa administered through a pump patch) | Parkinson\'s disease | 1 | NeuroDerm (Israel) | Neurodegenerative diseases - CNS diseases |
| 2013-03-02 | dupilumab | atopic dermatitis | 1b | Sanofi (France) Regeneron Pharmaceuticals (USA) | Dermatological diseases - Immunological diseases - Inflammatory diseases |
| 2013-02-28 | volasertib | acute myeloid leukemia (AML) | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2013-02-28 | TB-403 | medulloblastoma | preclinical | BioInvent International (Sweden) Thrombogenics (Belgium) | Cancer - Oncology |
